期刊
DERMATOLOGIC THERAPY
卷 34, 期 5, 页码 -出版社
WILEY
DOI: 10.1111/dth.15067
关键词
acral melanoma; adjuvant; cutaneous melanoma; interferon alpha-2b; PD-1 inhibitor
类别
资金
- Guangzhou Health and Family Planning Commission Technology Project [20191A1515011263]
- National Natural Science Foundation of China [81772910]
- Sun Yat-sen University Cancer Center for Distinguished Young Scholar [PT04180201]
This retrospective study found that adjuvant PD-1 inhibitors provided significantly longer RFS and DMFS in Chinese patients with stage IIIB/C cutaneous melanoma compared to high-dose interferon alpha-2b (HDI), but there was no significant advantage observed in patients with acral melanoma.
The clinical efficacy of PD-1 inhibitors as an adjuvant treatment for Asian melanoma patients has not yet been determined. This retrospective study analyzed the clinical data of 90 Chinese patients with completely resected, stage III cutaneous or acral melanoma who received either adjuvant PD-1 inhibitor or high-dose interferon alpha-2b (HDI). Anti-PD-1 treatment resulted in significantly longer RFS and DMFS than HDI in cutaneous melanoma patients, with hazard ratios (HRs) (anti-PD-1 versus HDI) of 0.402 (95% CI, 0.183-0.886) and 0.324 (95%CI, 0.122 to 0.861) for RFS and DMFS, respectively. However, adjuvant anti-PD-1 treatment had no advantage over HDI in acral melanoma patients with HRs (anti-PD-1 versus HDI) of 1.204 (95% CI, 0.521 to 2.781) and 1.968(95% CI, 0.744-5.209) for RFS and DMFS, respectively. Adjuvant anti-PD-1 treatment yielded a significantly better prognosis than HDI in Chinese patients with stage IIIB/C cutaneous melanoma, but a significant difference was not observed in those with acral melanoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据